Bleomycin pharmacokinetics of bolus bleomycin dose in elderly cancer patients treated with electrochemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 5, 2016, Pages 939-947

  Groselj, Ales ^a   Krzan, Mojca ^b   Kosjek, Tina ^c   Bosnjak, Masa ^d   Sersa, Gregor ^d   Cemazar, Maja ^d,e  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c JO EF STEFAN INSTITUTE   (Slovenia)

^d INSTITUTE OF ONCOLOGY   (Slovenia)

^e UNIVERSITY OF PRIMORSKA   (Slovenia)

Author keywords

Bleomycin; Elderly patients; Electrochemotherapy; Head and neck tumors; Pharmacokinetics; Skin metastases

Indexed keywords

BLEOMYCIN; ANTINEOPLASTIC ANTIBIOTIC;

AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ELECTROCHEMOTHERAPY; FEMALE; HEAD AND NECK CANCER; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METASTASIS; NON MELANOMA SKIN CANCER; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SECOND CANCER; SERUM; THERAPEUTIC INDEX; AREA UNDER THE CURVE; BLOOD; HEAD AND NECK NEOPLASMS; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; PROCEDURES; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SKIN NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; BLEOMYCIN; ELECTROCHEMOTHERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PROSPECTIVE STUDIES; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SKIN NEOPLASMS;

EID: 84961209062     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-3004-z     Document Type: Article

References (32)

1. Fyfe AJ, McKay P (2010) Toxicities associated with bleomycin. J R Coll Phys Edinb 40: 213–215. doi: 10.4997/JRCPE.2010.306
2. Della Latta V, Cecchettini A, Del Ry S, Morales MA (2015) Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions. Pharmacol Res 97: 122–130. doi: 10.1016/j.phrs.2015.04.012
3. Pron G, Mahrour N, Orlowski S, Tounekti O, Poddevin B, Belehradek J, Mir LM (1999) Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism. Biochem Pharmacol 57: 45–56. doi: 10.1016/S0006-2952(98)00282-2
4. Sugiura Y, Uesawa Y, Takahashi Y, Kuwahara J, Golik J, Doyle TW (1989) Nucleotide-specific cleavage and minor-groove interaction of DNA with esperamicin antitumor antibiotics. Proc Natl Acad Sci USA 86: 7672–7676
5. Ferrando AA, Velasco G, Campo E, Lopez-Otin C (1996) Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance. Cancer Res 56: 1746–1750
6. Pron G, Belehradek J Jr, Mir LM (1993) Identification of a plasma membrane protein that specifically binds bleomycin. Biochem Biophys Res Commun 194: 333–337. doi: 10.1006/bbrc.1993.1824
7. Buxton IO, Benet LZ (2011) Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination. In: Brunton LL, Chabner BA, Knollmann BC (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, 12th edn. McGraw-Hill, New York
8. Oken MM, Crooke ST, Elson MK, Strong JE, Shafer RB (1981) Pharmacokinetics of bleomycin after im administration in man. Cancer Treat Rep 65: 485–489
9. Bitran JD (1985) Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial. Cancer 56: 2420–2423
10. Howell SB, Schiefer M, Andrews PA, Markman M, Abramson I (1987) The pharmacology of intraperitoneally administered bleomycin. J Clin Oncol 5: 2009–2016
11. Hall SW, Strong JE, Broughton A, Frazier ML, Benjamin RS (1982) Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 9: 22–25
12. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M (2008) Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 34: 232–240. doi: 10.1016/j.ejso.2007.05.016
13. Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF (2010) Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther 23: 651–661. doi: 10.1111/j.1529-8019.2010.01370.x
14. Yarmush ML, Golberg A, Sersa G, Kotnik T, Miklavcic D (2014) Electroporation-based technologies for medicine: principles, applications, and challenges. Ann Rev Biomed Eng 16: 295–320. doi: 10.1146/annurev-bioeng-071813-104622
15. Miklavcic D, Mali B, Kos B, Heller R, Sersa G (2014) Electrochemotherapy: from the drawing board into medical practice. Biomed Eng Online 13: 29. doi: 10.1186/1475-925X-13-29
16. Domenge C, Orlowski S, Luboinski B, De Baere T, Schwaab G, Belehradek J Jr, Mir LM (1996) Antitumor electrochemotherapy: new advances in the clinical protocol. Cancer 77: 956–963
17. Mir LM, Gehl J, Sersa G, Collins CG, Garbaya JR, Billarda V, Geertsend PF, Rudolf Z, O’Sullivanf GC, Marty M (2006) Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. EJC Supp 4: 14–25
18. Eisenhauera EA, Therasseb P, Bogaertsc J, Schwartzd LH, Sargente D, Fordf R, Danceyg J, Arbuckh Gwytheri S, Mooneyg M, Rubinsteing L, Shankarg L, Doddg L, Kaplanj R, Lacombec D, Verweijk J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228–247. doi: 10.1016/j.ejca.2008.10.026
19. Groselj A, Kos B, Cemazar M, Urbancic J, Kragelj G, Bosnjak M, Veberic B, Strojan P, Miklavcic D, Sersa G (2015) Coupling treatment planning with navigation system: a new technological approach in treatment of head and neck tumors by electrochemotherapy. Biomed Eng Online 14(Suppl 3): S2. doi: 10.1186/1475-925X-14-S3-S2
20. Campana LG, Mali B, Sersa G, Valpione S, Giorgi CA, Strojan P, Miklavcic D, Rossi CR (2014) Electrochemotherapy in non-melanoma head and neck cancers: a retrospective analysis of the treated cases. Br J Oral Maxillofac Surg 52: 957–964. doi: 10.1016/j.bjoms.2014.08.004
21. Kenakin TP (ed) (2014) Tecniques for more effective and strategic drug discovery. In: A pharmacology primer, 4 edn. Academic Press, San Diego, pp 213–253
22. Yee GC, Crom WR, Lee FH, Smyth RD, Evans WE (1983) Bleomycin disposition in children with cancer. Clin Pharmacol Ther 33: 668–673
23. Alberts DS, Chen HS, Woolfenden JM, Moon TE, Chang SY, Hall JN, Himmelstein KJ, Gross J, Salmon SE (1979) Pharmacokinetics of bleomycin in man. III. Bleomycin 57Co Vs bleomycin. Cancer Chemother Pharmacol 3: 33–40
24. Mangoni AA, Jackson SH (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57: 6–14
25. Fulop T, Worum I, Csongor J, Foris G, Leovey A (1985) Bodycomposition in elderly people. 1. Determination of body-composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects. Gerontology 31: 6–14
26. Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D (2013) Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 39: 4–16. doi: 10.1016/j.ejso.2012.08.016
27. Cadossi R, Ronchetti M, Cadossi M (2014) Locally enhanced chemotherapy by electroporation: clinical experiences and perspective of use of electrochemotherapy. Future Oncol 10: 877–890. doi: 10.2217/fon.13.235
28. Valpione S, Campana LG, Pigozzo J, Chiarion-Sileni V (2015) Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib. Radiol Oncol 49: 71–74. doi: 10.2478/raon-2014-0035
29. Edhemovic I, Brecelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B, Jarm T, Kos B, Pavliha D, Grcar Kuzmanov B, Cemazar M, Snoj M, Miklavcic D, Gadzijev EM, Sersa G (2014) Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol 110: 320–327. doi: 10.1002/jso.23625
30. Solari N, Spagnolo F, Ponte E, Quaglia A, Lillini R, Battista M, Queirolo P, Cafiero F (2014) Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent. J Surg Oncol 109: 270–274. doi: 10.1002/jso.23481
31. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM (1993) Electrochemotherapy, a new antitumor treatment. First clinical phase I–II trial. Cancer 72: 3694–3700
32. Mir LM, Tounekti O, Orlowski S (1996) Bleomycin: revival of an old drug. Gen Pharmacol 27: 745–748